ERBB4 Primary Antibody
|Aliases||HER4; ALS19; p180erbB4|
|Formulation||Purified antibody in PBS with 0.05% sodium azide|
|Immunogen||Purified recombinant fragment of human ERBB4 (AA: 1159-1308) expressed in E. Coli.|
|Shipping Information||This product will ship in a box containing blue ice at a temperature of 4°C. Learn More|
|ICC (Immunocytochemistry)||1/50 - 1/200|
|FCM (Flow Cytometry)||1/200 - 1/400|
|WB (Western Blot)||1/500 - 1/2000|
Figure 1: Black line: Control Antigen (100 ng); Purple line: Antigen(10ng); Blue line: Antigen (50 ng); Red line: Antigen (100 ng);
Figure 2:Western blot analysis using ERBB4 mAb against human ERBB4 (AA: 1159-1308) recombinant protein. (Expected MW is 43.3 kDa)
Figure 3:Western blot analysis using ERBB4 mAb against HEK293 (1) and ERBB4 (AA: 1159-1308)-hIgGFc transfected HEK293 (2) cell lysate.
Figure 4:Immunofluorescence analysis of Hela cells using ERBB4 mouse mAb (green). Blue: DRAQ5 fluorescent DNA dye. Red: Actin filaments have been labeled with Alexa Fluor- 555 phalloidin. Secondary antibody from Fisher (Cat#: 35503)
Figure 5:Flow cytometric analysis of Hela cells using ERBB4 mouse mAb (green) and negative control (red).
|Description||This gene is a member of the Tyr protein kinase family and the epidermal growth factor receptor subfamily. It encodes a single-pass type I membrane protein with multiple cysteine rich domains, a transmembrane domain, a tyrosine kinase domain, a phosphotidylinositol-3 kinase binding site and a PDZ domain binding motif. The protein binds to and is activated by neuregulins and other factors and induces a variety of cellular responses including mitogenesis and differentiation. Multiple proteolytic events allow for the release of a cytoplasmic fragment and an extracellular fragment. Mutations in this gene have been associated with cancer. Alternatively spliced variants which encode different protein isoforms have been described; however, not all variants have been fully characterized.|
|References (references)||1.Neurosci Lett. 2012 Dec 7;531(2):209-14. |
2.EMBO Mol Med. 2013 Jul;5(7):1019-34.